Introduction
============

In Danish pharmacoepidemiological studies, use of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) are typically identified from prescription databases.[@b1-clep-6-155]--[@b3-clep-6-155] However, there is no consensus on whether adequate information on NSAID use can be obtained from such databases.[@b4-clep-6-155] Stratification by[@b4-clep-6-155] or adjustment for[@b5-clep-6-155],[@b6-clep-6-155] aspirin use has been abandoned or dismissed by some authors, who argue that since aspirin is available over the counter (OTC), use of this drug or other NSAIDs cannot be captured reliably in the Danish prescription registries.[@b4-clep-6-155]

The potential of prescription registries to capture individual-level use of aspirin and other NSAIDs is of interest in several contexts. One is whether these registries can be used to survey utilization of nonaspirin NSAIDs,[@b7-clep-6-155] which are associated with an increased risk of cardiovascular disease.[@b8-clep-6-155],[@b9-clep-6-155] The current evidence indicates that all nonaspirin NSAIDs increase the risk of heart failure, whereas the risk of thrombotic events varies according to type of drug.[@b9-clep-6-155] Use of selective cyclooxygenase(COX)-2 inhibitors (coxibs) is associated with the highest vascular risk, whereas naproxen appears to have the least harmful cardiovascular risk profile.[@b9-clep-6-155],[@b10-clep-6-155] Moreover, increasing evidence supports that traditional nonaspirin NSAIDs with high COX-2 selectivity, in particular diclofenac, have thrombogenic properties similar to coxibs.[@b9-clep-6-155] Despite these important differences in cardiovascular toxicity, no study has evaluated whether use of naproxen or diclofenac has changed since the concern about cardiovascular toxicity associated with COX-2 inhibiting agents was first raised in 2004.[@b8-clep-6-155]

We examined the utilization of NSAIDs in Denmark from 1999 to 2012, with specific focus on trends in nonaspirin NSAID use and the potential of prescription registries to capture individual-level use of aspirin and nonaspirin NSAIDs.

Methods
=======

We ascertained individual use of low-dose aspirin and nonaspirin NSAIDs using data from the Danish National Prescription Registry, with focus on trends in overall utilization, age and sex distribution, volume, and the proportion of total sales that was sold on prescription.

Setting
-------

The Danish National Health Service provides universal tax-supported health care, guaranteeing free and equal access to general practitioners and hospitals and partial reimbursement for prescribed medications, including NSAIDs.[@b11-clep-6-155] Individual-level linkage of all Danish databases is possible using the unique Danish personal identification number, which is assigned to each Danish citizen at birth and to residents upon immigration.[@b12-clep-6-155]

Pharmacies in Denmark are equipped with electronic accounting systems, which are primarily used to secure reimbursement from the National Health Service.[@b13-clep-6-155],[@b14-clep-6-155]

A detailed account of variables registered in the prescription registries has previously been described.[@b13-clep-6-155] Briefly, for each redeemed prescription, the patient's personal identification number, the type of drug prescribed according to the Anatomical Therapeutic Chemical (ATC) classification system,[@b15-clep-6-155] pack size (numbers of pills and daily defined doses), and the date of drug dispensing are transferred electronically from the pharmacies to prescription registries.[@b13-clep-6-155],[@b14-clep-6-155] Different dose units for the same pharmaceutical entity can also be identified separately in the prescription registries by use of product codes.[@b13-clep-6-155],[@b14-clep-6-155]

We used the web facility Medstat (<http://www.medstat.dk>) to retrieve data on NSAID sales in Denmark.[@b16-clep-6-155] This publicly available webpage from the Danish Serum Institute provides aggregate statistics on the sale of pharmaceutical preparations in Denmark since 1995 based on the data reported to the Danish National Prescription Registry.[@b14-clep-6-155],[@b16-clep-6-155] This reporting is mandatory, and Medstat statistics are complete from 1999 onwards. The registration of total drug sales (including OTC sales) facilitates computations of descriptive statistics, including for example the proportion of total sales sold on prescription, and allows for stratification by age, sex, region, and health care sector (primary or secondary).[@b16-clep-6-155]

OTC use in Denmark
------------------

OTC NSAIDs include aspirin in all preparations, diclofenac (during the period July 16, 2007 to December 14, 2008), and low-dose ibuprofen (200 mg tablets) since March 27, 1989.[@b17-clep-6-155],[@b18-clep-6-155] Regular users of aspirin or nonaspirin NSAIDs have an economic incentive to obtain the drugs by prescription due to the reimbursement through the Danish National Health Service's insurance program.

In an effort to reduce suicide attempts by overdoses of analgesics,[@b19-clep-6-155] the Danish Health Authorities have implemented several restrictions in the dispensing of OTC drugs since 2001.[@b20-clep-6-155]--[@b22-clep-6-155] First, packages of aspirin and paracetamol containing ≥30 tablets were labeled with red box warnings alerting parents to read the warnings in the package leaflet and to store the drugs in a safe place (October 1, 2004).[@b20-clep-6-155] More recently (March 7, 2011),[@b21-clep-6-155] OTC sales of aspirin, paracetamol, and ibuprofen were restricted to persons aged ≥18 years and at maximum one package per person per day. Just recently (September 20, 2013), each dispensing of OTC analgesics has been restricted to pack sizes containing a maximum of 10 g of aspirin (ie, 20 high-dose tablets), 10 g of paracetamol (ie, 20 tablets), or 4 g of ibuprofen (ie, 20 tablets).[@b22-clep-6-155]

Aspirin
-------

Aspirin (acetylsalicylic acid) has the characteristic analgesic, antipyretic, and anti-inflammatory properties of nonselective NSAIDs.[@b23-clep-6-155],[@b24-clep-6-155] In high doses (500 mg), the main indication for aspirin is pain relief (ATC group: N02BA01, N02BA51). At low doses (75--150 mg), aspirin is not an effective analgesic, but the drug has an antithrombotic effect conferred by inhibition of platelet aggregation by irreversible blockage of the COX-1 enzyme.[@b23-clep-6-155],[@b24-clep-6-155] Accordingly, the main indication for low-dose aspirin (ATC group: B01AC06) is prevention and treatment of occlusive vascular events in patients with coronary artery disease or ischemic stroke.[@b25-clep-6-155]

Nonaspirin NSAIDs
-----------------

The main indications for nonaspirin NSAIDs are inflammatory conditions and pain (ATC group: M01A).[@b23-clep-6-155] We excluded glucosamine (ATC: M01AX05) from the main group (M01A), as this agent does not possess the pharmacodynamic properties of nonaspirin NSAIDs.[@b26-clep-6-155]

We identified all individual drugs from each NSAID class on the Danish market; ie, butylpyrazolidines, acetic acids, enolic acids, proprionic acids, fenamic acids, nonacidics, and coxibs.[@b17-clep-6-155] We furthermore identified the six most frequently used nonaspirin NSAIDs, which, according to their COX-selectivity, could be classified as nonselective NSAIDs (ibuprofen and naproxen), older COX-2 inhibitors (diclofenac and etodolac), and coxibs (celecoxib and rofecoxib). The newer and older COX-2 inhibitors are almost similar in COX-2 selectivity when comparing the concentration of the drugs (IC~50~) required to inhibit COX-1 and COX-2 activity by 50%.[@b27-clep-6-155] For instance, the COX-1/COX-2 IC~50~ is 29 for diclofenac and 30 for celecoxib.[@b27-clep-6-155]

Statistical analyses
--------------------

We obtained sales statistics for the entire Danish population (5.6 million inhabitants as of 2012) from January 1, 1999 to December 31, 2012. The retrieval of sales statistics was restricted to the primary health care sector; ie, sales outside the hospital setting. In addition to pharmacies and nonpharmacy outlets, drug sales in the primary health care sector comprised sales from the Danish Serum Institute and in general practices.[@b16-clep-6-155]

First, we calculated and illustrated graphically the 1-year prevalence of low-dose aspirin users and nonaspirin NSAID users, overall and by sex and age groups (15--19 years, 20--39 years, 40--64 years, 65--79 years, and ≥80 years). Age was defined as age at first redeemed prescription each year. Results were calculated for nonaspirin NSAIDs overall as well as separately for each of the six most frequently used types. Secondly, we identified the proportion of all aspirin and nonaspirin NSAID sales that was dispensed on prescription each year in the study period.

Results
=======

Aspirin
-------

Aspirin was prescribed almost exclusively in low doses for cardiovascular prevention. The annual number of low-dose aspirin prescription users increased steadily from 232,213 (4.4%) in 1999 to 408,555 (7.3%) in 2012 ([Table 1](#t1-clep-6-155){ref-type="table"} and [Figure 1](#f1-clep-6-155){ref-type="fig"}). Age- and sex-stratified analyses for prescribed low-dose aspirin showed an equal sex distribution in 1999, but over time slightly more men than women redeemed prescriptions for aspirin (8.0% vs 6.7% in 2012) ([Figure 1](#f1-clep-6-155){ref-type="fig"}). Practically no use of low-dose aspirin occurred in individuals younger than 40 years, but the prevalence of use increased to around 5% in those between the ages of 40--64 years, 25% in those aged 65--79 years, and 40% in those aged 80 years or more in 2012 ([Figure 2A](#f2-clep-6-155){ref-type="fig"}). The proportion of total low-dose aspirin sales that was prescribed on an individual level increased steadily from 62% in 1999 to 92% in 2012 ([Table 2](#t2-clep-6-155){ref-type="table"} and [Figure 3](#f3-clep-6-155){ref-type="fig"}).

High-dose aspirin was sold alone or in combination with codeine (9.6 mg) or caffeine (50 mg). As a single-compound product, high-dose aspirin was prescribed to 3,233 persons (0.06%) in 1999 and 521 (0.009%) in 2012 ([Table 1](#t1-clep-6-155){ref-type="table"}). As a combination product, high-dose aspirin was prescribed to 6,340 (0.1%) in 1999 and 8,398 (0.2%) in 2012. The vast majority of total sales of high-dose aspirin both alone (90%--93%) or in combination tablets (97%--99%) were sold OTC ([Table 2](#t2-clep-6-155){ref-type="table"}).

Nonaspirin NSAIDs
=================

Each year, around 13%--15% of the total Danish population redeemed at least one prescription of nonaspirin NSAID between 1999 and 2012 ([Table 1](#t1-clep-6-155){ref-type="table"}). From age 10--15 years, the prevalence of use increased markedly with age ([Figure 2B](#f2-clep-6-155){ref-type="fig"}). The overall prescription pattern of nonaspirin NSAIDs varied during the study period. Thus, the 1-year prevalence of individuals redeeming at least one prescription increased from 13.6% (n=723,325) in 1999 to 15.5% (n=836,072) in 2004, before declining steadily to 13.1% (n=731,667) in 2012 ([Table 1](#t1-clep-6-155){ref-type="table"} and [Figure 1](#f1-clep-6-155){ref-type="fig"}). A similar pattern was observed among men and women ([Figure 1](#f1-clep-6-155){ref-type="fig"}). Individuals aged 80 years or above constituted the most frequent users of prescription nonaspirin NSAIDs until 2003, after which their use decreased to below that of individuals aged 40--79 years ([Figure 2B](#f2-clep-6-155){ref-type="fig"}). All nonaspirin NSAIDs were used more frequently among women than among men.

The decrease in nonaspirin NSAID use from 2004 was seen for all three types of nonaspirin NSAIDs; ie, nonselective NSAIDs, older COX-2 inhibitors, and coxibs ([Table 1](#t1-clep-6-155){ref-type="table"} and [Figure 4](#f4-clep-6-155){ref-type="fig"}). An exception was ibuprofen, for which the 1-year prevalence increased steadily from 6.5% in 1999 to 9.9% in 2012. Among other commonly used nonaspirin agents, use of naproxen decreased slightly from 1999 to 2004 (1.1% in 1999 and 0.7% in 2004) and remained stable thereafter. Diclofenac was consistently prescribed to around 4% of the Danish population until 2008, after which the prevalence decreased and reached 2% in 2012. Etodolac was prescribed to approximately 0.5% throughout the period (0.7% in 1999 and 0.5% in 2012). Celecoxib and rofecoxib comprised almost the entire sale of coxibs. These agents displayed a fairly similar pattern of use, increasing steeply after their introduction (on November 15, 1999 for rofecoxib and on May 15, 2000 for celecoxib) to surpass both naproxen and etodolac ([Figure 4](#f4-clep-6-155){ref-type="fig"}). After 2002, the use of coxibs began to decrease; after September 30, 2004, when rofecoxib was withdrawn from the market, celecoxib use decreased sharply, and it was only used by 0.04% of the population in 2012 ([Table 1](#t1-clep-6-155){ref-type="table"} and [Figure 4](#f4-clep-6-155){ref-type="fig"}). Stratified analyses according to age and sex ([Table S1](#SD1-clep-6-155){ref-type="supplementary-material"}) revealed that coxibs and etodolac were used almost entirely among individuals above 40 years, whereas ibuprofen, naproxen, and diclofenac constituted the most frequently used nonaspirin NSAIDs among younger individuals.

The proportion of nonaspirin NSAIDs dispensed on prescription in Denmark decreased from 85% in 1999 to 75% in 2012 ([Table 2](#t2-clep-6-155){ref-type="table"} and [Figure 3](#f3-clep-6-155){ref-type="fig"}). The OTC availability of diclofenac in part of 2007--2008 did not influence the overall prescription/OTC relation materially ([Table 2](#t2-clep-6-155){ref-type="table"}). Thus, low-dose (200 mg) ibuprofen accounted for practically all OTC use of nonaspirin NSAIDs between 1999 and 2012. Specifically, OTC use of low-dose ibuprofen accounted for 30%--35% of total ibuprofen sales and 15%--25% of total nonaspirin NSAID sales between 1999 and 2012 ([Figure 3](#f3-clep-6-155){ref-type="fig"}). The overall decrease in the proportion of nonaspirin NSAIDs dispensed by prescription reflected that OTC ibuprofen use increased more than the prescribed use of ibuprofen.

Discussion
==========

Both low-dose aspirin and nonaspirin NSAIDs were commonly used in the Danish population between 1999 and 2012. The proportions of total sales of low-dose aspirin or nonaspirin NSAIDs dispensed by prescription and thus captured in prescription registries were high: as of 2012, 92% for low-dose aspirin, 66% for ibuprofen and 100% for all other nonaspirin NSAIDs. The 1-year prevalence of prescribed low-dose aspirin increased throughout the period, particularly among men. Except for ibuprofen, the 1-year prevalence of nonaspirin NSAID use decreased after 2004. The decline was independent of age or sex, but there was a consistently higher prevalence of use in older age groups and among women. Use of coxibs decreased to near null after 2004. Interestingly, the use of diclofenac was reduced by half between 2008 and 2012, but no substantial change occurred in use of naproxen and etodolac.

OTC use of low-dose aspirin and nonaspirin NSAIDs is far less common in Denmark than in many other countries.[@b28-clep-6-155] Therefore, the potential for identification of NSAID use from prescription registries is high. Indeed, with the most recent restriction on pack sizes of OTC analgesics in Denmark,[@b22-clep-6-155] OTC use of NSAIDs is likely to decrease even further. In this context, it should be noted that while low-dose aspirin is used continuously for prevention of cardiovascular disease and a substantial proportion of high-dose nonaspirin NSAID therapy is also used on a chronic basis, high-dose aspirin and low-dose ibuprofen are mainly used as short-term treatment of transient pain conditions such as headaches, sports injuries, or backaches. Danish prescription registry data are thus reliable data sources for research on the effects of aspirin and nonaspirin NSAID exposure, especially when indicated for chronic use.

Assessment of low-dose aspirin use has the advantage, compared with many other medications, that the daily defined dose equals one pill per day.[@b17-clep-6-155] Thus, the expected number of exposure days from a prescription refill can be modeled from the number of pills per package.[@b1-clep-6-155] Using a more accurate exposure window in this way (rather than a fixed exposure-window) may help to reduce misclassification of aspirin use.

Because the prescription data are prospectively recorded, any misclassification of NSAID use due to nonadherence or OTC use of aspirin or ibuprofen would generally bias measures of associations towards the null. The magnitude of misclassification bias due to OTC use can be illustrated from a hypothetical cohort study examining the effect of drug exposure on a given outcome. Assuming that 15% of the population uses the drug every day, only two-thirds obtain the drug on prescription (as for ibuprofen), and an equal age distribution among new and long-term users, there will be no misclassification of the apparently exposed and only 5% (nondifferential) misclassification of the apparently nonexposed (as one-third of 15% will be OTC users who are not captured by the prescription registry). Considering another scenario with an exposure prevalence of 10% and prescription coverage of 50%, the misclassification will still be only 5%. Unless the relative risk measure is very high, misclassification of this magnitude has no practical impact on the relative risk estimate, rate difference, or etiologic fraction among the exposed. Only the etiologic fraction in the background population will be substantially underestimated from such misclassification. Moreover, the misclassification would be even less for drugs with a prevalence of use below 10%--15% (which is often the case). Finally, the bias generated by such misclassification would be even smaller if the drug with OTC availability is a confounder drug and not the primary exposure.

The withdrawal of rofecoxib contributed to the subsequent reduction in use of all coxibs following 2004, including celecoxib.[@b8-clep-6-155] The increased focus on the cardiovascular toxicity associated with nonaspirin NSAID use in general, and COX-2 selective NSAIDs in particular, may also have contributed to the overall decrease in prescribed nonaspirin NSAID use from 2004 onwards. The decrease in diclofenac use after 2008 may be a direct consequence of recommendations from the Danish Medicines Agency in 2008[@b29-clep-6-155] and Danish Society for Cardiology in 2009[@b30-clep-6-155] to use diclofenac with caution due to an increased risk of cardiovascular disease. Surprisingly, use of naproxen did not increase during the study period despite several studies pointing to a markedly lower cardiovascular risk profile of naproxen than of other nonaspirin NSAID agents.[@b9-clep-6-155],[@b10-clep-6-155] In contrast, both prescribed and OTC use of ibuprofen increased substantially from 1999. These patterns are difficult to explain as a rational response to concerns about cardiovascular toxicity of nonaspirin NSAIDs. Until 2004, however, the dominant discourse on NSAID toxicity concerned gastrointestinal bleeding. Among the traditional NSAIDs, ibuprofen has a well-established low gastrointestinal risk, whereas the gastrointestinal safety is lower for naproxen.[@b31-clep-6-155],[@b32-clep-6-155] Although the magnitude of cardiovascular versus gastrointestinal risks for individual NSAIDs is controversial,[@b33-clep-6-155] it is possible that preferences to a large extent still are driven mainly by the perceived gastrointestinal risks.

Whereas low-dose ibuprofen therapy seems safe,[@b34-clep-6-155],[@b35-clep-6-155] high-dose ibuprofen has also been associated with adverse cardiovascular events.[@b9-clep-6-155] Even though OTC ibuprofen is only available in 200 mg tablets, it is not possible to monitor the consumed number of pills and hence the daily dose. This is a concern, especially before September 20, 2013,[@b22-clep-6-155] because OTC drugs are often used in higher doses than recommended and with little attention to potential side effects.[@b28-clep-6-155]

Strengths and limitations
-------------------------

Using Medstat, we were able to obtain complete data on prescribed and total sales of all marketed NSAIDs for the entire Danish population during a 14-year period.[@b14-clep-6-155],[@b16-clep-6-155] We did not have information on the exact number of OTC users, but we had information on the proportions of total sales of aspirin or nonaspirin NSAID that were dispensed by prescription. The proportion of prescription use of all nonaspirin NSAIDs, except low-dose ibuprofen, equals almost all use in Denmark.

Conclusion
==========

The potential for identification of individual-level use of low-dose aspirin and nonaspirin NSAIDs from prescription registries in Denmark is high. This is of vast importance for analytical studies addressing NSAIDs as either primary or secondary exposures. The pattern of NSAID use in Denmark varied substantially between 1999 and 2012. Use of coxibs nearly ceased and diclofenac use decreased by half since 2008, whereas naproxen use remained stable and did not increase despite its less harmful cardiovascular risk profile.
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###### 

Annual prevalence of NSAID use in Denmark 1999--2012 stratified by age and sex categories

  Age groups                                                                 Sex      Number of prescription users in the primary sector per thousand Danish inhabitants                                                         
  -------------------------------------------------------------------------- -------- ------------------------------------------------------------------------------------ -------- -------- -------- -------- -------- -------- --------
  **Low-dose aspirin (B01AC06)**                                             43.70    45.68                                                                                56.77    64.77    70.71    76.19    76.74    73.21    
  All age groups                                                             Male     43.11                                                                                45.27    57.59    66.88    74.04    80.69    82.38    79.63
  Female                                                                     44.28    46.08                                                                                55.98    62.70    67.45    71.77    71.19    66.90    
  15--19 years                                                               Male     0.08                                                                                 0.11     0.09     0.15     0.15     0.27     0.27     0.32
  Female                                                                     0.09     0.13                                                                                 0.17     0.12     0.29     0.34     0.31     0.41     
  20--39 years                                                               Male     1.07                                                                                 1.19     1.77     2.27     2.54     2.90     2.74     2.39
  Female                                                                     1.07     1.15                                                                                 1.65     2.04     2.42     2.73     2.54     2.51     
  40--64 years                                                               Male     42.31                                                                                45.10    60.59    72.80    81.14    87.35    85.19    78.14
  Female                                                                     26.07    27.86                                                                                38.04    45.90    51.25    55.70    53.46    48.28    
  65--79 years                                                               Male     207.01                                                                               214.55   265.49   296.63   314.46   330.21   328.18   306.38
  Female                                                                     164.23   169.52                                                                               205.96   228.92   240.14   248.21   239.46   218.05   
  ≥80 years                                                                  Male     320.86                                                                               334.07   385.26   417.39   441.03   461.79   467.92   439.26
  Female                                                                     306.59   320.31                                                                               359.45   381.51   396.88   414.15   415.74   387.04   
  **Non-aspirin NSAIDs (M01A[a](#tfn10-clep-6-155){ref-type="table-fn"})**   136.13   139.06                                                                               152.95   154.90   151.87   146.79   140.49   131.11   
  All age groups                                                             Male     118.80                                                                               120.36   132.09   135.03   134.24   130.55   125.66   118.23
  Female                                                                     153.04   157.34                                                                               173.36   174.34   169.15   162.72   155.07   143.78   
  15--19 years                                                               Male     45.58                                                                                46.94    53.03    56.40    56.75    53.26    48.05    40.06
  Female                                                                     98.32    103.15                                                                               115.90   120.85   118.96   110.94   99.22    86.49    
  20--39 years                                                               Male     115.42                                                                               116.82   126.40   130.25   130.31   122.95   114.10   102.19
  Female                                                                     151.35   154.13                                                                               169.26   175.52   174.68   165.02   152.98   136.92   
  40--64 years                                                               Male     172.02                                                                               174.11   190.31   194.91   195.09   189.81   183.10   173.41
  Female                                                                     205.55   211.24                                                                               231.22   234.55   232.00   224.60   215.77   202.15   
  65--79 years                                                               Male     189.57                                                                               191.77   214.90   214.65   206.36   204.43   200.31   189.51
  Female                                                                     219.47   226.68                                                                               252.68   244.46   225.27   218.19   212.40   197.93   
  ≥80 years                                                                  Male     207.59                                                                               212.32   234.05   220.71   192.83   183.30   173.43   159.61
  Female                                                                     230.68   242.62                                                                               271.39   247.13   203.25   187.75   173.49   158.71   
  **Diclofenac (M01AB05)**                                                   38.96    38.98                                                                                39.37    41.50    41.63    41.37    27.08    19.75    
  All age groups                                                             Male     35.26                                                                                35.46    35.64    37.11    36.79    35.97    23.61    17.29
  Female                                                                     42.56    42.42                                                                                43.03    45.80    46.38    46.68    30.49    22.16    
  15--19 years                                                               Male     14.47                                                                                15.31    15.90    15.68    14.82    13.57    7.33     3.97
  Female                                                                     27.75    29.01                                                                                32.09    33.60    33.51    32.39    19.51    12.36    
  20--39 years                                                               Male     35.99                                                                                36.60    35.55    35.50    33.88    30.73    18.12    12.04
  Female                                                                     45.19    46.21                                                                                48.45    50.24    49.52    48.24    30.87    21.67    
  40--64 years                                                               Male     52.16                                                                                52.34    53.23    55.43    55.05    53.33    35.62    26.54
  Female                                                                     59.66    59.44                                                                                60.33    64.16    65.35    65.63    43.06    32.15    
  65--79 years                                                               Male     50.74                                                                                49.77    51.15    56.52    57.75    61.11    42.46    31.86
  Female                                                                     54.71    52.05                                                                                50.53    56.69    58.35    61.00    40.76    29.68    
  ≥80 years                                                                  Male     47.66                                                                                45.93    45.13    47.98    47.19    49.98    33.06    24.08
  Female                                                                     47.27    44.78                                                                                39.10    43.39    44.02    46.21    29.72    20.63    
  **Etodolac (M01AB08)**                                                     7.02     7.30                                                                                 8.69     11.11    9.94     9.40     6.87     5.15     
  All age groups                                                             Male     5.67                                                                                 5.95     7.15     8.33     7.29     6.95     5.05     3.78
  Female                                                                     8.35     8.62                                                                                 10.20    13.84    12.53    11.79    8.67     6.50     
  15--19 years                                                               Male     1.47                                                                                 1.44     1.60     1.26     1.10     0.95     0.78     0.54
  Female                                                                     2.47     2.81                                                                                 2.93     2.64     2.07     1.84     1.26     1.00     
  20--39 years                                                               Male     4.67                                                                                 4.90     5.48     5.15     4.13     3.68     2.49     1.70
  Female                                                                     5.71     5.94                                                                                 6.95     6.99     5.69     5.21     3.44     2.41     
  40--64 years                                                               Male     8.47                                                                                 8.80     10.58    12.14    10.43    9.88     7.09     5.30
  Female                                                                     11.99    12.49                                                                                14.64    19.34    17.38    16.37    11.97    8.87     
  65--79 years                                                               Male     10.67                                                                                11.08    14.45    19.01    17.20    16.56    12.01    9.08
  Female                                                                     15.98    16.00                                                                                19.64    30.28    28.01    26.13    19.84    14.76    
  ≥80 years                                                                  Male     12.77                                                                                14.98    17.52    27.24    24.83    23.11    16.65    11.54
  Female                                                                     16.47    17.05                                                                                20.32    35.86    33.41    30.57    21.86    16.33    
  **Ibuprofen (M01AE01)**                                                    65.09    65.62                                                                                73.83    83.54    89.73    91.63    98.83    99.45    
  All age groups                                                             Male     58.34                                                                                58.97    67.22    76.09    82.23    83.86    90.59    91.77
  Female                                                                     71.68    72.10                                                                                80.29    90.83    97.07    99.27    106.93   107.00   
  15--19 years                                                               Male     23.15                                                                                24.07    30.35    35.41    37.10    36.00    36.93    33.19
  Female                                                                     42.72    46.80                                                                                58.46    65.28    67.50    65.10    65.75    61.45    
  20--39 years                                                               Male     61.54                                                                                63.47    74.69    83.88    89.09    87.70    90.15    85.52
  Female                                                                     77.09    79.32                                                                                93.78    104.74   110.58   109.52   112.21   106.19   
  40--64 years                                                               Male     83.08                                                                                84.24    96.45    109.52   119.48   122.56   132.90   135.87
  Female                                                                     96.01    97.15                                                                                109.36   124.99   135.38   139.59   151.75   153.30   
  65--79 years                                                               Male     85.51                                                                                83.72    89.84    102.84   110.91   116.69   131.80   137.50
  Female                                                                     95.33    92.02                                                                                93.04    107.24   114.60   121.18   137.26   141.46   
  ≥80 years                                                                  Male     92.38                                                                                86.26    80.71    88.54    93.88    95.56    106.14   109.38
  Female                                                                     99.03    92.92                                                                                82.33    91.01    92.41    94.53    103.73   106.82   
  **Naproxen (M01AE02)**                                                     10.54    9.71                                                                                 8.09     7.13     6.01     6.01     6.73     7.27     
  All age groups                                                             Male     7.98                                                                                 7.28     6.13     5.40     4.57     4.62     5.44     5.96
  Female                                                                     13.04    12.08                                                                                10.00    8.82     7.41     7.37     8.00     8.56     
  15--19 years                                                               Male     3.31                                                                                 3.36     2.84     3.00     2.55     2.65     2.48     1.94
  Female                                                                     19.72    20.32                                                                                18.93    17.42    15.52    14.45    13.17    12.13    
  20--39 years                                                               Male     7.08                                                                                 6.51     5.31     4.40     3.45     3.32     3.92     3.85
  Female                                                                     15.68    14.78                                                                                12.50    11.13    9.02     8.56     8.73     8.92     
  40--64 years                                                               Male     11.68                                                                                10.68    8.90     7.55     6.28     6.17     6.99     7.55
  Female                                                                     15.28    13.91                                                                                11.33    9.68     7.89     8.01     8.93     9.97     
  65--79 years                                                               Male     13.42                                                                                11.98    10.21    8.91     7.65     7.74     9.21     10.62
  Female                                                                     13.34    11.83                                                                                8.78     7.63     6.38     6.23     7.74     9.02     
  ≥80 years                                                                  Male     13.75                                                                                11.49    9.73     8.87     6.42     5.95     7.38     9.30
  Female                                                                     13.75    11.37                                                                                7.75     5.88     4.76     4.93     6.01     6.93     
  **Celecoxib (M01AH01)**                                                    --       2.48                                                                                 14.00    9.34     0.60     0.37     0.41     0.44     
  All age groups                                                             Male     --                                                                                   1.55     9.60     6.15     0.38     0.27     0.34     0.38
  Female                                                                     --       3.39                                                                                 18.31    12.47    0.81     0.46     0.49     0.50     
  15--19 years                                                               Male     --                                                                                   0.07     0.69     0.40     0.02     0.01     0.01     0.03
  Female                                                                     --       0.17                                                                                 1.71     1.18     0.11     0.04     0.04     0.03     
  20--39 years                                                               Male     --                                                                                   0.59     4.02     2.27     0.19     0.12     0.10     0.11
  Female                                                                     --       0.99                                                                                 5.99     3.49     0.44     0.19     0.14     0.09     
  40--64 years                                                               Male     --                                                                                   2.28     13.36    8.17     0.53     0.42     0.47     0.46
  Female                                                                     --       4.56                                                                                 23.18    15.23    1.00     0.60     0.60     0.58     
  65--79 years                                                               Male     --                                                                                   4.59     27.44    18.10    0.88     0.67     1.12     1.26
  Female                                                                     --       8.86                                                                                 47.53    32.30    1.55     1.05     1.46     1.62     
  ≥80 years                                                                  Male     --                                                                                   6.05     43.72    31.81    1.80     0.83     0.77     0.94
  Female                                                                     --       11.27                                                                                65.58    50.15    3.13     1.51     1.16     1.14     
  **Rofecoxib (M01AH02)**                                                    0.24     8.82                                                                                 14.05    6.04     --       --       --       --       
  All age groups                                                             Male     0.15                                                                                 5.51     9.71     4.10     --       --       --       --
  Female                                                                     0.33     12.06                                                                                18.28    7.93     --       --       --       --       
  15--19 years                                                               Male     --                                                                                   0.27     0.74     0.31     --       --       --       --
  Female                                                                     0.01     0.65                                                                                 1.87     0.90     --       --       --       --       
  20--39 years                                                               Male     0.03                                                                                 1.91     4.15     1.69     --       --       --       --
  Female                                                                     0.06     3.13                                                                                 5.71     2.54     --       --       --       --       
  40--64 years                                                               Male     0.24                                                                                 7.92     13.14    5.48     --       --       --       --
  Female                                                                     0.44     15.73                                                                                22.30    9.35     --       --       --       --       
  65--79 years                                                               Male     0.45                                                                                 16.73    28.58    11.74    --       --       --       --
  Female                                                                     1.01     33.14                                                                                48.35    20.76    --       --       --       --       
  ≥80 years                                                                  Male     0.76                                                                                 24.47    44.92    20.01    --       --       --       --
  Female                                                                     0.99     41.58                                                                                69.97    31.82    --       --       --       --       

**Notes:** The sales information is based on data from the Danish National Prescription Registry. Age group 0--14 are not shown due to the low prevalence of use.

M01A, except glucosamine (M01AX05).

**Abbreviations:** COX, cyclooxygenase; NSAID, non-steroidal anti-inflammatory drug.
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![The 1-year prevalence of the Danish population redeeming a prescription for low-dose aspirin or nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) during 1999--2012, overall and by sex.](clep-6-155Fig1){#f1-clep-6-155}

![The 1-year prevalence of the Danish population redeeming a prescription for low-dose aspirin (**A**) or nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) (**B**) during 1999--2012, by age groups.](clep-6-155Fig2){#f2-clep-6-155}

![The percentage of total nonsteroidal anti-inflammatory drug (NSAID) sales sold on prescription in Denmark between 1999 and 2012.](clep-6-155Fig3){#f3-clep-6-155}

![The annual prevalence of the Danish population prescribed the most commonly used nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) (blue), older COX-2 inhibitors (red), and coxibs (green) between 1999 and 2012.\
**Abbreviation:** COX, cyclooxygenase.](clep-6-155Fig4){#f4-clep-6-155}

###### 

Annual prevalence of NSAID use in Denmark, 1999--2012

                                                                        Number of prescription users (per thousand Danish inhabitants)                                                                                                                                                 
  --------------------------------------------------------------------- ---------------------------------------------------------------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------------ -------------- -------------- --------------
  **Aspirin (salicylates)[a](#tfn2-clep-6-155){ref-type="table-fn"}**                                                                                                                                                                                                                  
   Low-dose                                                             232,213                                                          243,498    273,028    304,778    329,349    349,598    364,775    383,783    400,332    417,175    422,213      424,714        421,641        408,555
   (B01AC06)                                                            (43.70)                                                          (45.68)    (51.04)    (56.77)    (61.18)    (64.77)    (67.41)    (70.71)    (73.49)    (76.19)    (76.61)      (76.74)        (75.83)        (73.21)
   High-dose, alone                                                     3,233                                                            2,441      2,207      2,241      1,954      1,705      1,624      1,464      1,360      1,041      753          611            604            521
   (N02BA01)                                                            (0.61)                                                           (0.46)     (0.41)     (0.42)     (0.36)     (0.32)     (0.30)     (0.27)     (0.25)     (0.19)     (0.14)       (0.11)         (0.11)         (0.09)
   High-dose, combinations                                              6,340                                                            6,127      9,883      11,538     9,870      9,129      9,318      8,920      8,776      8,645      8,404        8,933          8,782          8,398
   (N02BA51)                                                            (1.19)                                                           (1.15)     (1.85)     (2.15)     (1.83)     (1.69)     (1.72)     (1.64)     (1.61)     (1.58)     (1.52)       (1.61)         (1.58)         (1.50)
  **Nonaspirin NSAIDs**                                                                                                                                                                                                                                                                
  Overall                                                               723,325                                                          741,211    787,337    821,108    824,860    836,072    829,866    824,291    810,211    803,767    775,676      777,592        768,223        731,667
  (M01A[b](#tfn3-clep-6-155){ref-type="table-fn"})                      (136.13)                                                         (139.06)   (147.19)   (152.95)   (153.22)   (154.90)   (153.35)   (151.87)   (148.74)   (146.79)   (140.74)     (140.49)       (138.15)       (131.11)
  Butylpyrazolidines                                                    1,154                                                            1,146      1,126      1,034      1,022      965        1,043      1,045      945        963        955          984            960            898
  (M01AA)                                                               (0.22)                                                           (0.22)     (0.21)     (0.19)     (0.19)     (0.18)     (0.19)     (0.19)     (0.17)     (0.18)     (0.17)       (0.18)         (0.17)         (0.16)
   Phenylbutazone                                                       1,154                                                            1,146      1,126      1,034      1,022      965        1,043      1,045      945        963        955          984            960            898
   (M01AA01)                                                            (0.22)                                                           (0.22)     (0.21)     (0.19)     (0.19)     (0.18)     (0.19)     (0.19)     (0.17)     (0.18)     (0.17)       (0.18)         (0.17)         (0.16)
  Acetic acids                                                          300,152                                                          291,352    283,354    279,832    276,974    299,663    314,257    307,328    296,884    288,303    212,287      200,008        183,438        147,235
  (M01AB)                                                               (56.49)                                                          (54.66)    (52.97)    (52.13)    (51.45)    (55.52)    (58.07)    (56.62)    (54.50)    (52.65)    (38.52)      (36.14)        (32.99)        (26.38)
   Indometacin                                                          14,418                                                           12,614     10,700     7,800      6,280      6,203      6,307      6,123      5,313      4,905      4,539        3,663          2,343          1,180
   (M01AB01)                                                            (2.71)                                                           (2.37)     (2.00)     (1.45)     (1.17)     (1.15)     (1.17)     (1.13)     (0.98)     (0.90)     (0.82)       (0.66)         (0.42)         (0.21)
   Sulindac                                                             848                                                              747        668        563        435        330        --         --         --         --         --           --             --             --
   (M01AB02)                                                            (0.16)                                                           (0.14)     (0.12)     (0.10)     (0.08)     (0.06)                                                                                            
   Tolmetin                                                             531                                                              424        132        --         --         --         --         --         --         --         --           --             --             --
   (M01AB03)                                                            (0.10)                                                           (0.08)     (0.02)                                                                                                                             
   Diclofenac                                                           206,995                                                          207,754    212,664    211,365    210,409    223,989    229,037    225,968    220,895    226,560    155,745      149,876        138,989        110,203
   (M01AB05)                                                            (38.96)                                                          (38.98)    (39.76)    (39.37)    (39.08)    (41.50)    (42.32)    (41.63)    (40.55)    (41.37)    (28.26)      (27.08)        (25.00)        (19.75)
   Etodolac                                                             37,319                                                           38,925     37,356     46,655     49,193     59,981     63,743     53,925     49,881     51,452     45,367       38,040         33,718         28,747
   (M01AB08)                                                            (7.02)                                                           (7.30)     (6.98)     (8.69)     (9.14)     (11.11)    (11.78)    (9.94)     (9.16)     (9.40)     (8.23)       (6.87)         (6.06)         (5.15)
   Ketorolac                                                            14                                                               16         12         9          7          4          6          9          5          8          12           7              9              8
   (M01AB15)                                                            (0.00)                                                           (0.00)     (0.00)     (0.00)     (0.00)     (0.00)     (0.00)     (0.00)     (0.00)     (0.00)     (0.00)       (0.00)         (0.00)         (0.00)
   Aceclofenac                                                          9,208                                                            6,806      5,130      3,573      2,784      2,021      1,319      474        --         --         --           --             --             --
   (M01AB16)                                                            (1.73)                                                           (1.28)     (0.96)     (0.67)     (0.52)     (0.37)     (0.24)     (0.09)                                                                      
   Diclofenac, combinations                                             44,752                                                           34,386     24,978     18,406     15,705     16,188     25,648     31,100     30,130     19,419     12,318       13,040         12,367         9,783
   (M01AB55)                                                            (8.42)                                                           (6.45)     (4.67)     (3.43)     (2.92)     (3.00)     (4.74)     (5.73)     (5.53)     (3.55)     (2.23)       (2.36)         (2.22)         (1.75)
  Enolic acids                                                          46,180                                                           36,958     30,762     26,414     22,850     21,632     21,835     20,172     16,724     13,932     11,125       8,706          7,989          6,656
  (M01AC)                                                               (8.69)                                                           (6.93)     (5.75)     (4.92)     (4.24)     (4.01)     (4.03)     (3.72)     (3.07)     (2.54)     (2.02)       (1.57)         (1.44)         (1.19)
   Piroxicam                                                            30,165                                                           25,072     21,095     18,290     15,693     14,554     14,514     13,909     11,064     8,885      6,368        3,962          4,210          3,811
   (M01AC01)                                                            (5.68)                                                           (4.70)     (3.94)     (3.41)     (2.92)     (2.70)     (2.68)     (2.56)     (2.03)     (1.62)     (1.16)       (0.72)         (0.76)         (0.68)
   Tenoxicam                                                            9,474                                                            7,121      5,512      4,175      3,492      3,252      3,118      2,480      2,126      1,767      1,677        1,413          1,183          692
   (M01AC02)                                                            (1.78)                                                           (1.34)     (1.03)     (0.78)     (0.65)     (0.60)     (0.58)     (0.46)     (0.39)     (0.32)     (0.30)       (0.26)         (0.21)         (0.12)
   Lornoxicam                                                           409                                                              1,124      1,311      1,453      1,362      1,437      1,511      1,511      1,419      1,631      1,787        1,872          1,255          909
   (M01AC05)                                                            (0.08)                                                           (0.21)     (0.25)     (0.27)     (0.25)     (0.27)     (0.28)     (0.28)     (0.26)     (0.30)     (0.32)       (0.34)         (0.23)         (0.16)
   Meloxicam                                                            6,598                                                            4,029      2,996      2,600      2,413      2,490      2,801      2,355      2,186      1,726      1,567        1,535          1,371          1,280
   (M01AC06)                                                            (1.24)                                                           (0.76)     (0.56)     (0.48)     (0.45)     (0.46)     (0.52)     (0.43)     (0.40)     (0.32)     (0.28)       (0.28)         (0.25)         (0.23)
  Proprionic acids                                                      417,401                                                          414,299    427,744    449,657    466,934    499,718    530,752    534,783    535,047    552,703    589,621      602,457        608,115        605,594
  (M01AE)                                                               (78.55)                                                          (77.73)    (79.96)    (83.76)    (86.73)    (92.58)    (98.08)    (98.53)    (98.23)    (100.94)   (106.98)     (108.85)       (109.36)       (108.52)
   Ibuprofen                                                            345,864                                                          349,731    370,105    396,325    418,826    450,903    480,615    486,987    487,208    501,768    529,284      547,003        555,753        554,969
   (M01AE01)                                                            (65.09)                                                          (65.62)    (69.19)    (73.83)    (77.80)    (83.54)    (88.82)    (89.73)    (89.44)    (91.63)    (96.03)      (98.83)        (99.94)        (99.45)
   Naproxen                                                             56,007                                                           51,749     46,302     43,422     39,974     38,468     37,030     32,601     30,940     32,901     43,047       37,256         37,856         40,571
   (M01AE02)                                                            (10.54)                                                          (9.71)     (8.66)     (8.09)     (7.43)     (7.13)     (6.84)     (6.01)     (5.68)     (6.01)     (7.81)       (6.73)         (6.81)         (7.27)
   Ketoprofen                                                           15,905                                                           14,144     12,579     11,023     9,881      9,407      8,517      7,988      7,771      7,291      6,504        5,506          3,867          1,050
   (M01AE03)                                                            (2.99)                                                           (2.65)     (2.35)     (2.05)     (1.84)     (1.74)     (1.57)     (1.47)     (1.43)     (1.33)     (1.18)       (0.99)         (0.70)         (0.19)
   Fenoprofen                                                           294                                                              244        208        164        75         --         --         --         --         --         --           --             --             --
   (M01AE04)                                                            (0.06)                                                           (0.05)     (0.04)     (0.03)     (0.01)                                                                                                       
   Fenbufen                                                             68                                                               39         --         --         --         --         --         --         --         --         --           --             --             --
   (M01AE05)                                                            (0.01)                                                           (0.01)                                                                                                                                        
   Flurbiprofen                                                         433                                                              298        241        196        177        180        157        143        122        122        108          89             --             --
   (M01AE09)                                                            (0.08)                                                           (0.06)     (0.05)     (0.04)     (0.03)     (0.03)     (0.03)     (0.03)     (0.02)     (0.02)     (0.02)       (0.02)                        
   Tiaprofenic acid                                                     7,679                                                            5,725      4,612      3,441      2,179      2,201      2,146      1,753      904        809        616          504            510            564
   (M01AE11)                                                            (1.45)                                                           (1.07)     (0.86)     (0.64)     (0.40)     (0.41)     (0.40)     (0.32)     (0.17)     (0.15)     (0.11)       (0.09)         (0.09)         (0.10)
   Dexibuprofen                                                         --                                                               --         938        2,194      2,625      6,214      10,902     13,684     16,548     19,648     22,297       20,676         18,538         17,373
   (M01AE14)                                                                                                                                        (0.18)     (0.41)     (0.49)     (1.15)     (2.01)     (2.52)     (3.04)     (3.59)     (4.05)       (3.74)         (3.33)         (3.11)
   Dexketoprofen (M01AE17)                                              --                                                               --         --         --         --         --         --         --         --         --         693 (0.13)   3,242 (0.59)   3,169 (0.57)   2,538 (0.45)
   Naproxen + esomeprazole (M01AE52)                                    --                                                               --         --         --         --         --         --         --         --         --         --           --             --             138 (0.02)
  Fenamic acids                                                         16,573                                                           16,973     17,419     17,882     18,747     18,884     17,507     16,100     14,686     5,228      6,007        5,736          5,321          5,193
  (M01AG)                                                               (3.12)                                                           (3.18)     (3.26)     (3.33)     (3.48)     (3.50)     (3.24)     (2.97)     (2.70)     (0.95)     (1.09)       (1.04)         (0.96)         (0.93)
   Tolfenamic acid                                                      16,573                                                           16,973     17,419     17,882     18,747     18,884     17,507     16,100     14,686     5,228      6,007        5,736          5,321          5,193
   (M01AG02)                                                            (3.12)                                                           (3.18)     (3.26)     (3.33)     (3.48)     (3.50)     (3.24)     (2.97)     (2.70)     (0.95)     (1.09)       (1.04)         (0.96)         (0.93)
  Nonacidics                                                            8,599                                                            6,086      4,106      3,305      5,653      9,811      12,000     9,645      6,877      6,122      5,221        4,555          3,441          2,999
  (M01AX)                                                               (1.62)                                                           (1.14)     (0.77)     (0.62)     (1.05)     (1.82)     (2.22)     (1.78)     (1.26)     (1.12)     (0.95)       (0.82)         (0.62)         (0.54)
   Nabumetone                                                           8,599                                                            6,086      4,106      3,305      5,653      9,811      12,000     9,645      6,877      6,122      5,221        4,555          3,441          2,999
   (M01AX01)                                                            (1.62)                                                           (1.14)     (0.77)     (0.62)     (1.05)     (1.82)     (2.22)     (1.78)     (1.26)     (1.12)     (0.95)       (0.82)         (0.62)         (0.54)
  Coxibs                                                                1,294                                                            58,086     121,424    143,833    128,462    88,430     10,302     5,551      4,273      3,942      3,642        3,656          4,175          3,729
  (M01AH)                                                               (0.24)                                                           (10.90)    (22.70)    (26.79)    (23.86)    (16.38)    (1.90)     (1.02)     (0.78)     (0.72)     (0.66)       (0.66)         (0.75)         (0.67)
   Celecoxib                                                            --                                                               13,215     62,346     75,174     64,207     50,435     6,798      3,233      2,318      2,026      2,105        2,295          2,515          2,447
   (M01AH01)                                                                                                                             (2.48)     (11.66)    (14.00)    (11.93)    (9.34)     (1.26)     (0.60)     (0.43)     (0.37)     (0.38)       (0.41)         (0.45)         (0.44)
   Rofecoxib                                                            1,294                                                            47,014     65,828     75,402     61,406     32,582     --         --         --         --         --           --             --             --
   (M01AH02)                                                            (0.24)                                                           (8.82)     (12.31)    (14.05)    (11.41)    (6.04)                                                                                            
   Etoricoxib                                                           --                                                               --         --         --         8,778      13,071     3,578      2,334      1,967      1,924      1,541        1,368          1,663          1,284
   (M01AH05)                                                                                                                                                              (1.63)     (2.42)     (0.66)     (0.43)     (0.36)     (0.35)     (0.28)       (0.25)         (0.30)         (0.23)

**Notes:** Some nonaspirin NSAID groups have synonyms: Enolic acids = oxicams, fenamic acids = fenamates, nonacidics = naphthyl alkanone, and coxibs = newer COX-2 inhibitors. The sales information is based on data from the Danish National Prescription Registry.

Low-dose aspirin (75--150 mg) for cardiovascular prevention and high-dose (500 mg) for pain relief (alone or in combination with 9.6 mg codeine \[Kodimagnyl^®^\] or 50 mg caffeine \[Treo^®^\])

M01A, except glucosamine (M01AX05).

**Abbreviations:** COX, cyclooxygenase; NSAID, nonsteroidal anti-inflammatory drug.

###### 

The percentage of total NSAID sales sold on prescription in Denmark, 1999--2012

                                                                        1999   2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012
  --------------------------------------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  **Aspirin (salicylates)[a](#tfn6-clep-6-155){ref-type="table-fn"}**                                                                                              
   Low-dose (B01AC06)                                                   62     63     71     77     82     85     87     89     90     90     90     91     91     92
   High-dose, alone (N02BA01)                                           7      7      7      8      8      9      9      9      9      9      10     10     9      10
   High-dose, combinations (N02BA51)                                    1      1      1      2      2      2      2      2      2      2      2      3      3      3
  **Nonaspirin NSAIDs**                                                                                                                                            
  Overall (M01A[b](#tfn7-clep-6-155){ref-type="table-fn"})              85     84     85     85     85     84     83     82     82     81     80     79     77     75
  Butylpyrazolidines (M01AA)                                            97     95     95     96     98     97     99     99     99     \>99   99     \>99   \>99   \>99
   Phenylbutazone (M01AA01)                                             97     95     95     96     98     97     99     99     99     \>99   99     \>99   \>99   \>99
  Acetic acids (M01AB)                                                  99     99     98     98     98     99     99     99     99     98     99     99     99     99
   Indometacin (M01AB01)                                                99     98     99     98     97     99     99     99     99     \>99   \>99   \>99   \>99   99
   Sulindac (M01AB02)                                                   \>99   \>99   \>99   \>99   \>99   \>99   --     --     --     --     --     --     --     --
   Tolmetin (M01AB03)                                                   \>99   \>99   \>99   --     --     --     --     --     --     --     --     --     --     --
   Diclofenac (M01AB05)                                                 98     98     98     98     98     98     98     98     98     97     98     99     99     99
   Etodolac (M01AB08)                                                   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99
   Ketorolac (M01AB15)                                                  19     35     14     13     37     37     42     33     3      3      5      4      3      2
   Aceclofenac (M01AB16)                                                \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   --     --     --     --     --     --
   Diclofenac, combinations (M01AB55)                                   99     99     99     99     99     99     99     99     99     99     \>99   \>99   \>99   \>99
  Enolic acids (M01AC)                                                  98     98     98     98     98     97     97     97     98     99     98     99     99     99
   Piroxicam (M01AC01)                                                  98     97     97     97     97     97     97     98     99     98     98     99     99     99
   Tenoxicam (M01AC02)                                                  \>99   \>99   \>99   \>99   \>99   \>99   \>99   99     99     99     99     99     99     \>99
   Lornoxicam (M01AC05)                                                 96     78     93     90     92     89     72     68     71     92     89     94     96     97
   Meloxicam (M01AC06)                                                  \>99   \>99   99     99     99     99     \>99   \>99   \>99   \>99   \>99   \>99   99     \>99
  Proprionic acids (M01AE)                                              76     74     73     72     71     71     72     72     72     72     73     72     70     69
   Ibuprofen (M01AE01)                                                  70     68     68     67     67     67     69     69     69     69     69     69     67     66
   Naproxen (M01AE02)                                                   99     98     98     99     98     99     99     99     99     99     99     99     99     99
   Ketoprofen (M01AE03)                                                 99     99     99     99     99     99     99     99     99     99     99     \>99   \>99   \>99
   Fenoprofen (M01AE04)                                                 \>99   \>99   \>99   \>99   \>99   --     --     --     --     --     --     --     --     --
   Fenbufen (M01AE05)                                                   \>99   \>99   --     --     --     --     --     --     --     --     --     --     --     --
   Flurbiprofen (M01AE09)                                               \>99   \>99   \>99   \>99   99     \>99   \>99   \>99   \>99   \>99   \>99   \>99   --     --
   Tiaprofenic acid (M01AE11)                                           \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99
   Dexibuprofen (M01AE14)                                               --     --     \>99   \>99   97     99     \>99   \>99   99     98     98     99     99     99
   Dexketoprofen (M01AE17)                                              --     --     --     --     --     --     --     --     --     --     97     98     \>99   \>99
   Naproxen and esomeprazole (M01AE52)                                  --     --     --     --     --     --     --     --     --     --     --     --     --     99
  Fenamic acids (M01AG)                                                 99     99     99     99     99     99     99     99     \>99   \>99   99     99     \>99   \>99
   Tolfenamic acid (M01AG02)                                            99     99     99     99     99     99     99     99     \>99   \>99   99     99     \>99   \>99
  Nonacidics (M01AX)                                                    \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99
   Nabumetone (M01AX01)                                                 \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99   \>99
  Coxibs (M01AH)                                                        97     \>99   99     99     99     99     98     98     90     94     99     99     99     99
   Celecoxib (M01AH01)                                                  --     99     \>99   \>99   99     \>99   97     98     85     92     99     99     99     99
   Rofecoxib (M01AH02)                                                  \>99   \>99   99     99     98     99     --     --     --     --     --     --     --     --
   Etoricoxib (M01AH05)                                                 --     --     --     --     \>99   \>99   \>99   \>99   \>99   \>99   99     99     99     99

**Notes:** Some nonaspirin NSAID groups have synonyms: Enolic acid = oxicams, fenamic acids = fenamates, nonacidics = naphthyl alkanone, and coxibs = newer COX-2 inhibitors. The sales information is based on data from the Danish National Prescription Registry. Even for prescription drugs only, the proportion sold on prescription does not equal exactly 100% because there are small nonperson referable sale for use in general practices, by the Danish Serum Institute, and for medicine stocks at nursing homes and treatment centers. Nonperson referable sale may influence the proportion sold on prescription more when the drug is rarely prescribed (eg, ketorolac).

Low-dose aspirin (75--150 mg) for cardiovascular prevention and high dose (500 mg) for pain relief (alone or in combination with 9.6 mg codeine \[Kodimagnyl^®^\] or 50 mg caffeine \[Treo^®^\])

M01A, except glucosamine (M01AX05).

**Abbreviations:** COX, cyclooxygenase; NSAID, nonsteroidal anti-inflammatory drug.
